Gentronix Agrees Genotoxicity Safety Screening Agreement with GSK for Greenscreen HC
News Feb 25, 2009
Gentronix Limited [Manchester, UK] has announced that it has entered into an agreement to provide GlaxoSmithKline (GSK) with its novel genotoxicity detection assay GreenScreen HC.
GreenScreen HC is said to be the first human cell based assay technology that combines high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive results. The assay is amenable to high throughput screening, provides additional data for safety profiling, consumes very low quantities of compound and gives rapid results.
The proprietary reporter based assay detects all known classes of genotoxic agent and utilizes Green Fluorescent Protein in order to detect GADD-45a up-regulation which is a key indicator of DNA damage.
John Nicholson, CEO and Chairman of Gentronix said ‘we have worked with GSK previously on the early validation of our technology and are delighted that they will be incorporating GreenScreen HC into their safety evaluation activities. This agreement provides important validation of our technology and demonstrates the value we bring to our customers’
Financial terms of the agreement were not released.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE